Drugs / LIQ865B
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02982889 | Dec 2016 → Mar 2017 | — | Liquidia Technologies, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIQ865B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982889 ↗ |
| Known as | bupivacaine | “LIQ865A and LIQ865B are two distinct formulations of bupivacaine manufactured via Liquidia Technologies PRINT (Particle Replication In Non-wetting Templates), which Liquidia...” NCT02982889 ↗ |
| Route | Subcutaneous | “Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg” NCT02982889 ↗ |